BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 35038570)

  • 1. Subcutaneous versus transvenous implantable defibrillator in patients with hypertrophic cardiomyopathy.
    Jankelson L; Garber L; Sherrid M; Massera D; Jones P; Barbhaiya C; Holmes D; Knotts R; Bernstein S; Spinelli M; Park D; Aizer A; Chinitz L
    Heart Rhythm; 2022 May; 19(5):759-767. PubMed ID: 35038570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical course of hypertrophic cardiomyopathy patients implanted with a transvenous or subcutaneous defibrillator.
    Francia P; Ziacchi M; Adduci C; Ammendola E; Pieragnoli P; De Filippo P; Rapacciuolo A; Rella V; Migliore F; Viani S; Musumeci MB; Biagini E; Lovecchio M; Baldini R; Falasconi G; Autore C; Biffi M; Cecchi F
    Europace; 2023 Aug; 25(9):. PubMed ID: 37724686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The need for a subsequent transvenous system in patients implanted with subcutaneous implantable cardioverter-defibrillator.
    Gasperetti A; Schiavone M; Vogler J; Laredo M; Fastenrath F; Palmisano P; Ziacchi M; Angeletti A; Mitacchione G; Kaiser L; Compagnucci P; Breitenstein A; Arosio R; Vitali F; De Bonis S; Picarelli F; Casella M; Santini L; Pignalberi C; Lavalle C; Pisanò E; Ricciardi D; Calò L; Curnis A; Bertini M; Gulletta S; Dello Russo A; Badenco N; Tondo C; Kuschyk J; Tilz R; Forleo GB; Biffi M
    Heart Rhythm; 2022 Dec; 19(12):1958-1964. PubMed ID: 35781042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary prevention implantable cardioverter-defibrillators in hypertrophic cardiomyopathy-Are there predictors of appropriate therapy?
    Weissler-Snir A; Dorian P; Rakowski H; Care M; Spears D
    Heart Rhythm; 2021 Jan; 18(1):63-70. PubMed ID: 32800967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
    Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eligibility for the Subcutaneous Implantable Cardioverter-Defibrillator in Patients With Hypertrophic Cardiomyopathy.
    Francia P; Adduci C; Palano F; Semprini L; Serdoz A; Montesanti D; Santini D; Musumeci B; Salvati A; Volpe M; Autore C
    J Cardiovasc Electrophysiol; 2015 Aug; 26(8):893-899. PubMed ID: 25996259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-Term Clinical Outcomes of Subcutaneous Versus Transvenous Implantable Defibrillator Therapy.
    Brouwer TF; Yilmaz D; Lindeboom R; Buiten MS; Olde Nordkamp LR; Schalij MJ; Wilde AA; van Erven L; Knops RE
    J Am Coll Cardiol; 2016 Nov; 68(19):2047-2055. PubMed ID: 27810043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Propensity score matched comparison of subcutaneous and transvenous implantable cardioverter-defibrillator therapy in the SIMPLE and EFFORTLESS studies.
    Brouwer TF; Knops RE; Kutyifa V; Barr C; Mondésert B; Boersma LVA; Lambiase PD; Wold N; Jones PW; Healey JS
    Europace; 2018 Sep; 20(FI2):f240-f248. PubMed ID: 29771327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strength of clinical indication and therapeutic impact of the implantable cardioverter defibrillator in patients with hypertrophic cardiomyopathy.
    Fumagalli C; De Filippo V; Zocchi C; Tassetti L; Marra MP; Brunetti G; Baritussio A; Cipriani A; Bauce B; Carrassa G; Maurizi N; Zampieri M; Calore C; De Lazzari M; Berteotti M; Pieragnoli P; Corrado D; Olivotto I
    Int J Cardiol; 2022 Apr; 353():62-67. PubMed ID: 35031346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of subcutaneous ICD early performance in hypertrophic cardiomyopathy from the pooled EFFORTLESS and IDE cohorts.
    Lambiase PD; Gold MR; Hood M; Boersma L; Theuns DAMJ; Burke MC; Weiss R; Russo AM; Kääb S; Knight BP
    Heart Rhythm; 2016 May; 13(5):1066-1074. PubMed ID: 26767422
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Appropriate Shocks and Antitachycardia Pacing in Transvenous and Subcutaneous Implantable Defibrillators: Analysis of All Appropriate Therapy in the PRAETORIAN Trial.
    Knops RE; van der Stuijt W; Delnoy PPHM; Boersma LVA; Kuschyk J; El-Chami MF; Bonnemeier H; Behr ER; Brouwer TF; Kääb S; Mittal S; Quast ABE; Smeding L; Tijssen JGP; Bijsterveld NR; Richter S; Brouwer MA; de Groot JR; Kooiman KM; Lambiase PD; Neuzil P; Vernooy K; Alings M; Betts TR; Bracke FALE; Burke MC; de Jong JSSG; Wright DJ; Jansen WPJ; Whinnet ZI; Nordbeck P; Knaut M; Philbert BT; van Opstal JM; Chicos AB; Allaart CP; Borger van der Burg AE; Clancy JF; Dizon JM; Miller MA; Nemirovsky D; Surber R; Upadhyay GA; Weiss R; de Weger A; Wilde AAM; Olde Nordkamp LRA;
    Circulation; 2022 Feb; 145(5):321-329. PubMed ID: 34779221
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Left intraventricular pressure gradient in hypertrophic cardiomyopathy patients receiving implantable cardioverter-defibrillators for primary prevention.
    Yazaki K; Suzuki A; Shiga T; Minami Y; Arai K; Ashihara K; Shoda M; Hagiwara N
    BMC Cardiovasc Disord; 2021 Feb; 21(1):106. PubMed ID: 33607967
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and programming strategies of implantable cardioverter-defibrillator devices in paediatric hypertrophic cardiomyopathy: a UK National Cohort Study.
    Norrish G; Chubb H; Field E; McLeod K; Ilina M; Spentzou G; Till J; Daubeney PEF; Stuart AG; Matthews J; Hares D; Brown E; Linter K; Bhole V; Pillai K; Bowes M; Jones CB; Uzun O; Wong A; Yue A; Sadagopan S; Bharucha T; Yap N; Rosenthal E; Mathur S; Adwani S; Reinhardt Z; Mangat J; Kaski JP
    Europace; 2021 Mar; 23(3):400-408. PubMed ID: 33221861
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitachycardia pacing for shock prevention in patients with hypertrophic cardiomyopathy and ventricular tachycardia.
    Dallaglio PD; di Marco A; Moreno Weidmann Z; Perez L; Alzueta J; García-Alberola A; Fernandez-Lozano I; Díaz-Infante E; Rodriguez A; Basterra N; Calvo D; Rodriguez Garcia M; Aceña M; Anguera I
    Heart Rhythm; 2020 Jul; 17(7):1084-1091. PubMed ID: 32113896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting therapies in Japanese hypertrophic cardiomyopathy patients with an implantable cardioverter-defibrillator using the 2014 European Society of Cardiology guidelines.
    Nakano M; Kondo Y; Nakano M; Kajiyama T; Miyazawa K; Hayashi T; Ito R; Takahira H; Kobayashi Y
    Heart Vessels; 2021 Jan; 36(1):99-104. PubMed ID: 32666207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Worldwide differences in primary prevention implantable cardioverter defibrillator utilization and outcomes in hypertrophic cardiomyopathy.
    Nauffal V; Marstrand P; Han L; Parikh VN; Helms AS; Ingles J; Jacoby D; Lakdawala NK; Kapur S; Michels M; Owens AT; Ashley EA; Pereira AC; Rossano JW; Saberi S; Semsarian C; Ware JS; Wittekind SG; Day S; Olivotto I; Ho CY
    Eur Heart J; 2021 Oct; 42(38):3932-3944. PubMed ID: 34491319
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Benefits of cardiac pacing in ICD recipients with hypertrophic cardiomyopathy.
    Jiménez-Sánchez D; Castro-Urda V; Toquero-Ramos J; Restrepo-Córdoba MA; Sánchez-García M; García-Izquierdo E; Veloza D; Baena-Herrera J; González-López E; Domínguez F; García-Pavía P; Fernández-Lozano I
    J Interv Card Electrophysiol; 2022 Jan; 63(1):165-174. PubMed ID: 33594661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implantable cardioverter defibrillators for primary prevention of sudden death in hypertrophic cardiomyopathy.
    Konstantinou DM; Efthimiadis GK; Vassilikos V; Paraskevaidis S; Pagourelias E; Maron BJ; Karvounis H
    J Cardiovasc Med (Hagerstown); 2016 Jun; 17(6):433-9. PubMed ID: 26885981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Implantable cardioverter-defibrillator in patients with hypertrophic cardiomyopathy: efficacy and complications of the therapy in long-term follow-up.
    Syska P; Przybylski A; Chojnowska L; Lewandowski M; Sterliński M; Maciag A; Gepner K; Pytkowski M; Kowalik I; Maczyńska-Mazuruk R; Ruzyłło W; Szwed H
    J Cardiovasc Electrophysiol; 2010 Aug; 21(8):883-9. PubMed ID: 20132378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.